Roche

On September 8, 2014, Roche launched the Cobas 6800/8800 Systems, a highly automated, high-throughput molecular diagnostic system. These systems are designed to improve laboratory efficiency by providing faster test results with enhanced capabilities to accommodate high volumes of testing. This innovation by Roche supports clinical laboratories in delivering reliable and timely diagnostics results, thus improving patient care through rapid diagnostics. This launch underlines Roche's leadership in the diagnostics market and its commitment to laboratory excellence.

On May 5, 2015, Roche announced a strategic partnership with Foundation Medicine, a company specializing in molecular information and genomic analysis. This partnership includes a $1 billion investment and aims to advance cancer research and treatment by combining Foundation Medicine’s expertise in genomic profiling with Roche's resources in oncology. The collaboration focuses on developing precision medicine solutions to better understand cancer progression and deliver tailored treatment options, underscoring Roche's commitment to personalized healthcare.

In June 2017, the U.S. FDA approved Ocrevus (ocrelizumab), a groundbreaking treatment for patients with relapsing and primary progressive forms of multiple sclerosis (MS). Ocrevus is the first drug approved for primary progressive MS, providing significant hope to patients with this debilitating disease. The approval was based on data that demonstrated higher efficacy of Ocrevus compared to other MS treatments, offering a new standard of care for managing MS symptoms and progression, marking a significant achievement for Roche in neurology.

Roche acquired Flatiron Health in March 2018, a cutting-edge company focused on oncology-specific electronic health record software and the development of real-world evidence for cancer research. This acquisition allows Roche to improve its personalized healthcare strategy by integrating Flatiron’s expertise in data analytics and cancer care. The integration of real-world evidence in Roche’s cancer drug development process is expected to improve clinical trials and treatment outcomes, solidifying Roche's leadership in oncology.

Roche's acquisition of Spark Therapeutics was finalized in December 2019, marking a strategic move into gene therapy. Spark Therapeutics is known for its work in treating genetic diseases, including Luxturna, a one-time gene therapy product. This acquisition allows Roche to advance its capabilities in gene therapy and strengthen its presence in the field of rare diseases, positioning the company at the forefront of medical innovation. The deal valued at $4.8 billion demonstrates Roche's commitment to expanding its scientific excellence and leadership in precision medicine.

On June 15, 2020, the U.S. Food and Drug Administration (FDA) approved Roche's Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), for the treatment of patients with unresectable or metastatic hepatocellular carcinoma. This approval marked a significant advancement in the treatment options for this type of liver cancer. The combination therapy was shown to improve overall survival rates compared to the existing standard of care, positioning Roche as a leader in cancer immunotherapy.

On March 23, 2021, the World Health Organization (WHO) granted Emergency Use Listing (EUL) for Roche's SARS-CoV-2 Antigen Test Nasal. This test allows for rapid and reliable testing of COVID-19 infections and is suitable for use in a variety of settings. The approval by WHO expands global access to crucial testing resources during the COVID-19 pandemic, supporting efforts to control the virus's spread by facilitating widespread, quick, and accurate testing.

In November 2022, Roche launched a state-of-the-art digital diagnostics platform called Navify to enhance clinical decision support. Navify is designed to provide healthcare professionals with actionable insights generated from vast sets of data, integrating advanced analytics and clinical decision support systems. The platform aids in making informed decisions quickly and supports personalized healthcare solutions. Roche's Navify demonstrates the company's commitment to digital innovation in healthcare, aiming to transform data into knowledge to optimize patient care.

In February 2023, Roche completed the acquisition of GenMark Diagnostics, a company known for its molecular diagnostic solutions. This acquisition allows Roche to enhance its portfolio of molecular diagnostics and expands its capabilities in the detection of a various range of pathogens and potential antimicrobial resistance genes. GenMark's technology complements Roche’s existing business and supports its strategic objectives in the personalized healthcare market.

In May 2023, Roche announced the expansion of its global biologics manufacturing network to increase the production of innovative biologics medicines. This expansion includes new facilities and upgrades in various global locations, enhancing Roche's capacity to meet growing demands for biologics production. It reflects Roche's commitment to innovation in biologics, ensuring a steady supply of high-quality medicines for patients worldwide. This strategic expansion supports Roche’s goal to deliver advanced biologic therapies to patients.